GSK’s Andrew Witty: Addressing Neglected Tropical Diseases and Global Health Issues — The Pharmaceutical Patent Pool (A)
(15 pages of text)
Case (Pub Mat)
In February 2009, Andrew Witty, CEO of GlaxoSmithKline (GSK), reflected on his vision for big pharma as a catalyst for change which focussed on two key issues: 1) promoting innovation for the products that treat or prevent neglected tropical diseases and 2) improving access to medicines in the world’s poorest countries. He had announced the creation of the Pharmaceutical Patent Pool and wondered if it was the right strategy to deliver results on these two key issues.
The (A) case can be used as a standalone case or in conjunction with the (B) case. Both cases focus on the charge against GSK that it values profits over people, especially with regard to less economically developed nations. After engaging with the case materials, students should be able to:
Demonstrate an understanding of the complexity of making decisions in emotionally fraught international contexts.
Argue for or against GSK’s patent pool program, and describe the differences between the traditional pharmaceutical business model and the patent pool business model.
Show competence in stakeholder mapping and demonstrate a deep understanding of stakeholders’ points of view.
United Kingdom;Global, Large, 2009
$4.25 CAD / $4.25 USD Printed Copy
$3.75 CAD / $3.75 USD Permissions
$3.75 CAD / $3.75 USD Digital Download